Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (PAUSE)
Anthropometry (3)
- Bmi at Screening (kg m2) - Subject BMI at Screening (phv00533228.v1.p1)
- Height of subject at Screening (cm) - Subject height at Screening in centimeters (cm) (phv00533227.v1.p1)
- Weight of subject at Screening (kg) - Subject weight at Screening in kilograms (kg) (phv00533226.v1.p1)
Demographics (3)
- Age - Age at screening (phv00533223.v1.p1)
- Sex - Self-reported sex (phv00533222.v1.p1)
- Sex - Subject Sex (phv00533217.v1.p1)
Race and Ethnicity (2)
- Ethnicity - Self-reported enthnicity (phv00533225.v1.p1)
- Race - Self-reported race (phv00533224.v1.p1)
Other (16)
- Baseline DLQI Score - Subject DLQJ Score (phv00533233.v1.p1)
- Baseline PASE Score - Subject PASE Score (phv00533231.v1.p1)
- Baseline PASI Score - Subject PASI Score (phv00533229.v1.p1)
- Baseline Percent Body Surface Area Psor - Subject Baseline Percent Body Surface Area Psor (phv00533230.v1.p1)
- Baseline PGA Score - Subject Baseline PGA Score (phv00533232.v1.p1)
- BODY_SITE - Collection site for the sample (phv00533236.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00533216.v1.p1)
- Planned Treatment for Period 01 (N) - Planned Treatment for Period 1 (phv00533221.v1.p1)
- Planned Treatment for Period 02 (N) - Planned Treatment for Period 2 (phv00533234.v1.p1)
- SAMPLE_ID - Sample ID (phv00533235.v1.p1)
- SAMPLE_ID - Sample ID (phv00533219.v1.p1)
- SPECIMEN_TYPE - Specimen Type (phv00533237.v1.p1)
- SPECIMEN_TYPE_DESC - Specimen Type Description (phv00533238.v1.p1)
- SUBJECT_ID - Subject ID (phv00533220.v1.p1)
- SUBJECT_ID - Subject ID (phv00533215.v1.p1)
- SUBJECT_ID - Subject ID (phv00533218.v1.p1)